Keywords: kabi, linomide, phase, iii, aml, pharmacia, immunomodulator

KABI'S LINOMIDE IN PHASE III FOR AML

Article | 16 August 1993

Kabi Pharmacia's immunomodulator compound Linomide (roquinimex) has now entered Phase III testing as a treatment for acute myeloid leukemia patients. ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pharmacia

Go to company listing